• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Poll

Click here to answer this week's poll.

Which 2022 Psoriasis FDA Approval Were You Most Excited About?

Deucravacitinib
Tapinarof cream
Roflumilast cream
Spesolimab (generalized pustular psoriasis)
Related Videos
Related Content
Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis

Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis

Article
The Cutaneous Connection: An Inside Look of the Inclusive Atlas

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Podcast
Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

Article
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Podcast
ARCA Biopharma and Oruka Therapeutics Agree to Merger

ARCA Biopharma and Oruka Therapeutics Agree to Merger

Article
Discovering Dermatology Times: March 2024 Enhancing Psoriasis Management Supplement

Discovering Dermatology Times: March 2024 Enhancing Psoriasis Management Supplement

Article
© 2024 MJH Life Sciences

All rights reserved.